Parkinson's Disease/Movement Disorders News

Biopharmaceutical company AbbVie has submitted a new drug application to the FDA for ABBV-951, a 24-hour subcutaneous treatment for motor fluctuations in patients with advanced Parkinson's disease.

The FDA has approved Radicava ORS oral suspension for the treatment of adults with ALS.

Stealth BioTherapeutics Corp. announced that the FDA has granted orphan drug designation to elamipretide for the treatment of Duchenne muscular dystrophy.

The FDA announced it will review a resubmitted supplemental new drug application for Nuplazid for the treatment of hallucinations and delusions associated with Alzheimer’s disease psychosis.

The Parkinson’s Foundation has expanded its PD GENEration study, a national initiative that offers no-cost genetic testing and counseling to those with Parkinson’s disease, to 23 actively enrolling participant sites.

Neuroscience company Cerevance announced the completion of its phase 2 clinical trial of CVN424, a once-daily oral compound developed for the treatment of Parkinson’s disease.

Boston Scientific Corp. announced it has received FDA approval for its image-guided software for deep brain stimulation therapy in patients with Parkinson’s disease.

SEATTLE — A decrease in the severity of tics in children and adolescents with Tourette syndrome was observed following the use of ecopipam, according to data presented at the 2022 American Academy of Neurology annual meeting.

In this week's edition, the FDA approval of a transdermal patch to treat Alzheimer’s-related dementia; the link between daily napping and an increased risk for Alzheimer’s disease; an oral treatment for Parkinson’s; and more.

SEATTLE — Sage Therapeutics will be starting a randomized, controlled trial in patients with Alzheimer’s disease, Aaron Koenig, MD, the company’s vice president of early clinical development, said at the 2022 American Academy of Neurology annual meeting.